LUPIN Financial Statement Analysis
|
||
|
The Revenues of LUPIN have increased by 1.44% YoY .
The Earnings Per Share (EPS) of LUPIN has increased by 344.55 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
LUPIN Last 5 Annual Financial Results
[BOM: 500257|NSE : LUPIN]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹16,642 Cr | ₹16,405 Cr | ₹15,163 Cr | ₹15,375 Cr | ₹14,665 Cr |
| Expenses | ₹14,921 Cr | ₹16,190 Cr | ₹12,596 Cr | ₹13,020 Cr | ₹12,104 Cr |
| Operating Profit (Excl OI) | ₹1,721 Cr | ₹215 Cr | ₹2,567 Cr | ₹2,355 Cr | ₹2,561 Cr |
| Other Income | ₹151 Cr | ₹214 Cr | ₹136 Cr | ₹484 Cr | ₹333 Cr |
| Interest | ₹274 Cr | ₹143 Cr | ₹141 Cr | ₹363 Cr | ₹302 Cr |
| Depreciation | ₹881 Cr | ₹1,659 Cr | ₹887 Cr | ₹970 Cr | ₹846 Cr |
| Profit Before Tax | ₹716 Cr | ₹-1,372 Cr | ₹1,676 Cr | ₹757 Cr | ₹1,409 Cr |
| Profit After Tax | ₹448 Cr | ₹-1,509 Cr | ₹1,228 Cr | ₹-400 Cr | ₹521 Cr |
| Consolidated Net Profit | ₹430 Cr | ₹-1,528 Cr | ₹1,217 Cr | ₹-269 Cr | ₹607 Cr |
| Earnings Per Share (Rs) | ₹42.01 | ₹9.45 | ₹-33.62 | ₹26.81 | ₹-5.95 |
| PAT Margin (%) | 6.10 | 1.57 | -5.09 | 4.34 | -1.34 |
| ROE(%) | 14.61 | 3.68 | -11.79 | 9.47 | -3.09 |
| ROCE(%) | 16.24 | 6.06 | -7.11 | 9.71 | 5.45 |
| Total Debt/Equity(x) | 0.19 | 0.34 | 0.32 | 0.35 | 0.51 |
Key Financials |
||
| Market Cap | : | ₹ 89,906.8 Cr |
| Revenue (TTM) | : | ₹ 22,001.6 Cr |
| Net Profit(TTM) | : | ₹ 2,892.1 Cr |
| EPS (TTM) | : | ₹ 63.3 |
| P/E (TTM) | : | 31.1 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| LUPIN | -0.1% | -2% | 19.1% |
| SUN PHARMACEUTICAL INDUSTRIES | -1.3% | 4.7% | 3.3% |
| DIVIS LABORATORIES | 1.9% | 1.5% | 41.9% |
| CIPLA | 3.4% | 0.1% | -3.1% |
| TORRENT PHARMACEUTICALS | -4.8% | 1.9% | 20.3% |
| DR REDDYS LABORATORIES | -0.1% | -1% | -11.3% |
| MANKIND PHARMA | -4% | 4% | -1.9% |
| ZYDUS LIFESCIENCES | 0.2% | -2.8% | -15.6% |
| AUROBINDO PHARMA | -2% | -0.9% | -5.7% |
LUPIN Revenues
[BOM: 500257|NSE : LUPIN]
| Y-o-Y | 1.44 % |
| 5 Yr CAGR | 3.21 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹16,642 Cr | 1.44 | |
| Mar2023 | ₹16,405 Cr | 8.19 | |
| Mar2022 | ₹15,163 Cr | -1.38 | |
| Mar2021 | ₹15,375 Cr | 4.84 | |
| Mar2020 | ₹14,665 Cr | - | |
LUPIN Operating Profit
[BOM: 500257|NSE : LUPIN]
| Y-o-Y | 699.37 % |
| 5 Yr CAGR | -9.46 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹1,721 Cr | 699.37 | |
| Mar2023 | ₹215 Cr | -91.61 | |
| Mar2022 | ₹2,567 Cr | 9.01 | |
| Mar2021 | ₹2,355 Cr | -8.04 | |
| Mar2020 | ₹2,561 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 689.31 % |
| 5 Yr CAGR | -12.28 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 10.34% | 689.31 | |
| Mar2023 | 1.31% | -92.26 | |
| Mar2022 | 16.93% | 10.51 | |
| Mar2021 | 15.32% | -12.26 | |
| Mar2020 | 17.46% | - | |
LUPIN Profit After Tax
[BOM: 500257|NSE : LUPIN]
| Y-o-Y | Positive |
| 5 Yr CAGR | -8.24 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹430 Cr | Positive | |
| Mar2023 | ₹-1,528 Cr | Negative | |
| Mar2022 | ₹1,217 Cr | Positive | |
| Mar2021 | ₹-269 Cr | Negative | |
| Mar2020 | ₹607 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 288.54 % |
| 5 Yr CAGR | Positive |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | 6.1 % | 288.54 | |
| Mar2023 | 1.57 % | Positive | |
| Mar2022 | -5.09 % | Negative | |
| Mar2021 | 4.34 % | Positive | |
| Mar2020 | -1.34 % | - | |
LUPIN Earnings Per Share (EPS)
[BOM: 500257|NSE : LUPIN]
| Y-o-Y | 344.55 % |
| 5 Yr CAGR | Positive |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹42 | 344.55 | |
| Mar2023 | ₹9.45 | Positive | |
| Mar2022 | ₹-34 | Negative | |
| Mar2021 | ₹27 | Positive | |
| Mar2020 | ₹-5.95 | - | |
LUPIN Return on Capital Employed (ROCE)
[BOM: 500257|NSE : LUPIN]
| Y-o-Y | 167.99 % |
| 5 Yr CAGR | 31.39 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 16.24% | 167.99 | |
| Mar2023 | 6.06% | Positive | |
| Mar2022 | -7.11% | Negative | |
| Mar2021 | 9.71% | 78.17 | |
| Mar2020 | 5.45% | - | |
LUPIN Share Price vs Sensex
| Current Share Price | : | ₹1,969.1 |
| Current MarketCap | : | ₹ 89,906.8 Cr |
| Updated EOD on | : | Apr 11,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| LUPIN | -0.1% |
-2% |
19.1% |
| SENSEX | -1.5% |
1.1% |
1.2% |
LUPIN related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE 100 ESG INDEX | -1.4% | 1.9% | 4.2% |
| BSE 100 | -1.9% | 1.6% | 1.4% |
| BSE 200 | -2.1% | 1.5% | 0.4% |
| BSE LARGEMIDCAP | -2.2% | 1.5% | -0.2% |
| BSE 250 LARGEMIDCAP INDEX | -2.2% | 1.5% | 0.2% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY LOW VOLATILITY 50 | -0.5% | 3.5% | 6.1% |
| NIFTY ALPHA LOW-VOLATILITY 30 | -1.6% | 1.9% | -5.7% |
| NIFTY 200 | -2.2% | 1.7% | 0.6% |
| NIFTY 500 | -2.3% | 1.5% | 0.2% |
| NIFTY TOTAL MARKET | -2.4% | 1.4% | 0.2% |
You may also like the below Video Courses
FAQ about LUPIN Financials
How the annual revenues of LUPIN have changed ?
The Revenues of LUPIN have increased by 1.44% YoY .
How the Earnings per Share (EPS) of LUPIN have changed?
The Earnings Per Share (EPS) of LUPIN has increased by 344.55 % YoY .
Check out Intrinsic Value of Peers of LUPIN
Compare Stock Analytics of Peers of LUPIN
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
